KALV

KalVista Pharmaceuticals, Inc. Common Stock

16.94

USD

KALV Earnings Reports

Positive Surprise Ratio

KALV beat 24 of 36 last estimates.

67%

Next Report

Next Week

Date of Next Report

Mar 17, 2026

Estimate for Q3 27 (Revenue/ EPS)

$29.27M

-$0.51

Implied change from Q4 26 (Revenue/ EPS)

Implied change from Q3 26 (Revenue/ EPS)

KalVista Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Jan 08, 2026, KALV reported earnings of -- USD per share (EPS) for Q4 26, -- the estimate of -0.63 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 22.62 million, with a --% difference. The market reacted with a +6.19% price change (close before vs. close after earnings).

Looking ahead to Q3 27, -- analysts forecast an EPS of -0.51 USD, with revenue projected to reach 29.27 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.45

Actual

-$0.42

Surprise

+6.77%

Esperion Therapeutics, Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

$0.24

Actual

$0.22

Surprise

-10.46%

Nektar Therapeutics

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.52

Actual

-$1.78

Surprise

+29.47%

Zevra Therapeutics, Inc. Common Stock

Report Date

Mar 09, 2026 For Q4 25

Estimate

$0.05

Actual

$0.21

Surprise

+311.76%

SIGA Technologies Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

Actual

-$0.08

Surprise

Nature's Sunshine Products Inc.

Report Date

Mar 10, 2026 For Q4 25

Estimate

$0.19

Actual

$0.30

Surprise

+54.80%

Century Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.28

Actual

-$0.25

Surprise

+13.49%

Corbus Pharmaceuticals Holdings, Inc.

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$1.60

Actual

-$1.25

Surprise

+22.24%

Verrica Pharmaceuticals Inc. Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.81

Actual

-$0.51

Surprise

+37.05%

Champions Oncology, Inc.

Report Date

Mar 12, 2026 For Q3 26

Estimate

$0.09

Actual

-$0.02

Surprise

-121.79%

FAQ

What were KalVista Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?

For Q4 2026, KalVista Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to KalVista Pharmaceuticals, Inc. Common Stock's Q4 2026 earnings?

The stock price moved up 6.19%, changed from $15.82 before the earnings release to $16.80 the day after.

When is KalVista Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 17, 2026.

What are the forecasts for KalVista Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on -- analysts, KalVista Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.51 and revenue of $29.27M for Q3 2027.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.